Blog Details

Type 3 Diabetes

Type 3 Diabetes

Type 3 Diabetes

Type 3 Diabetes: The Hidden Link Between Diabetes and Alzheimer’s Disease

Introduction

The term “Type 3 Diabetes” is often used to describe the hypothesized connection between insulin resistance in the brain and the development of Alzheimer’s disease. While not officially recognized as a medical diagnosis, the concept of Type 3 Diabetes highlights the role of impaired glucose metabolism in cognitive decline and neurodegeneration (de la Monte, 2014).

At the Diabetes Reversal Clinic (DRC) by EliteAyurveda, we integrate Ayurvedic principles with modern insights to address the root causes of metabolic and cognitive disorders, offering a holistic approach to prevent and manage Type 3 Diabetes (Sharma, 2018).

Type 3 Diabetes

Type 3 Diabetes

What Is Type 3 Diabetes?

Type 3 Diabetes refers to:

  • Insulin Resistance in the Brain: Impaired insulin signaling affects glucose uptake by brain cells, leading to energy deficits and neuronal damage (de la Monte, 2014).
  • Link to Alzheimer’s Disease: Insulin resistance is believed to contribute to the formation of amyloid plaques and neurofibrillary tangles, hallmark features of Alzheimer’s disease (Craft, 2005).

Causes of Type 3 Diabetes

1. Insulin Resistance and Type 2 Diabetes

  • Chronic high blood sugar levels lead to insulin resistance, not just in the body but also in the brain.
  • Individuals with Type 2 diabetes have a significantly higher risk of developing Alzheimer’s disease (Biessels et al., 2006).

2. Inflammation and Oxidative Stress

  • Chronic inflammation and free radical damage contribute to neuronal degeneration (Puglielli et al., 2003).

3. Lifestyle Factors

  • Sedentary habits, high-sugar diets, and poor sleep quality exacerbate insulin resistance and cognitive decline (Craft & Watson, 2004).

4. Genetic Predisposition

  • Genes such as APOE-e4 are associated with an increased risk of Alzheimer’s and may interact with metabolic dysfunction to accelerate neurodegeneration (Corder et al., 1993).

Symptoms of Type 3 Diabetes

  1. Cognitive Decline: Memory loss, confusion, and difficulty concentrating.
  2. Mood Changes: Increased anxiety, depression, or irritability.
  3. Impaired Problem-Solving Skills: Difficulty planning or managing daily tasks.
  4. Physical Signs: Overlapping symptoms with Type 2 diabetes, such as fatigue and poor energy levels (de la Monte, 2014).

Ayurveda’s Perspective on Type 3 Diabetes

In Ayurveda, cognitive decline and neurodegeneration are linked to:

  • Imbalance in Vata Dosha: Vata governs the nervous system, and its aggravation leads to neurological disorders.
  • Weak Agni (Digestive Fire): Impaired digestion creates toxins (Ama) that affect the brain.
  • Accumulation of Toxins (Ama): Ama obstructs subtle energy channels (Srotas), disrupting communication between neurons (Sharma, 2018).

Ayurvedic Approach to Managing Type 3 Diabetes

1. Detoxification (Shodhana)

  • Goal: Remove toxins (Ama) that impair cognitive function.
  • Therapies: Gentle detox therapies and dietary adjustments to cleanse the system (Chauhan, 2021).

2. Rejuvenation (Rasayana Therapy)

  • Goal: Restore neuronal health and improve brain function.
  • Therapies: Personalized potent herbal preparations to enhance memory, focus, and overall cognitive health (Gupta & Singh, 2017).

3. Diet for Cognitive Health

  • Focus: A Vata-pacifying diet that includes:
    • Whole grains (quinoa, millet).
    • Nuts and seeds (almonds, walnuts, flaxseeds).
    • Anti-inflammatory spices like turmeric and cinnamon.
  • Avoid: Processed sugars, fried foods, and excessive caffeine (Sharma, 2018).

4. Lifestyle Practices

  • Yoga and Meditation: Practices such as Shavasana and Pranayama calm the mind and reduce stress.
  • Sleep Hygiene: Establishing consistent sleep patterns to support brain health (Miller & Thompson, 2020).

Success Story: Managing Type 3 Diabetes with Ayurveda

Patient Profile

  • Name: Meera
  • Age: 62
  • Condition: Early-stage Alzheimer’s with Type 2 diabetes.
  • Symptoms: Forgetfulness, difficulty concentrating, and elevated HbA1c (8.5%).

Intervention at DRC

  1. Dietary Adjustments: A low-glycemic, anti-inflammatory diet with memory-enhancing foods like walnuts and ghee (Sharma, 2018).
  2. Herbal Medications: Personalized formulations to enhance cognitive function and stabilize blood sugar (Gupta & Singh, 2017).
  3. Detox and Rejuvenation: Detox therapies to remove toxins and Rasayana therapy for brain health (Chauhan, 2021).
  4. Yoga and Pranayama: Daily breathing exercises to reduce stress and improve focus (Miller & Thompson, 2020).

Outcome

  • Cognitive Improvement: Better memory retention and reduced confusion.
  • Blood Sugar Levels: HbA1c reduced to 6.8% in six months.
  • Overall Health: Increased energy and emotional well-being (EliteAyurveda, 2023).

From the Doctor’s Desk

Dr. Soumya Hullanavar shares:
“Type 3 Diabetes highlights the intricate connection between metabolic health and brain function. By addressing the root causes through Ayurveda, we can not only prevent cognitive decline but also support long-term brain health. At the Diabetes Reversal Clinic, we tailor treatments to empower patients on their journey to holistic well-being.” (Hullanavar, 2023)

Practical Tips for Preventing and Managing Type 3 Diabetes

  1. Monitor Blood Sugar Levels: Regular testing can help identify and manage insulin resistance (American Diabetes Association, 2022).
  2. Adopt an Anti-Inflammatory Diet: Focus on foods rich in antioxidants and healthy fats.
  3. Stay Physically Active: Exercise improves insulin sensitivity and promotes brain health (Miller & Thompson, 2020).
  4. Reduce Stress: Incorporate mindfulness practices to lower cortisol levels.
  5. Prioritize Sleep: Aim for 7–8 hours of quality sleep to support cognitive function (Sharma, 2018).

Why Choose the Diabetes Reversal Clinic?

  1. Holistic Approach: Integrating modern science with Ayurvedic wisdom for comprehensive care.
  2. Personalized Care: Treatments tailored to individual health profiles and needs.
  3. Expert Guidance: Led by Dr. Soumya Hullanavar, a specialist in managing diabetes and related conditions.
  4. Proven Results: Real-life success stories of patients managing and improving their health naturally (EliteAyurveda, 2023).

Conclusion

Type 3 Diabetes is a growing concern that underscores the critical link between brain health and metabolic disorders. With Ayurveda’s holistic approach, it is possible to address the root causes, prevent cognitive decline, and enhance overall well-being. At the Diabetes Reversal Clinic, we provide the tools and guidance you need to manage this condition effectively.

📞 Contact us today: +91 8884722267
🌐 Visit: Diabetes Reversal Clinic

Related-

Know more about Ayurveda Diabetes Reversal Treatments.

GET IN TOUCH

Schedule a Visit

Contact us

References

Click here for references

1.Saeedi P., Petersohn I., Salpea P., Malanda B., Karuranga S., Unwin N., Colagiuri S., Guariguata L., Motala A.A., Ogurtsova K., et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res. Clin. Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843. [DOI] [PubMed] [Google Scholar]

2.Ngoc N.B., Lin Z.L., Ahmed W. Diabetes: What Challenges Lie Ahead for Vietnam? Ann. Glob. Health. 2020;86:1. doi: 10.5334/aogh.2526. [DOI] [PMC free article] [PubMed] [Google Scholar]

3.Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442. doi: 10.1371/journal.pmed.0030442. [DOI] [PMC free article] [PubMed] [Google Scholar]

4.Nguyen T.T., Giau V.V., Vo T.K. Current advances in transdermal delivery of drugs for Alzheimer’s disease. Indian J. Pharmacol. 2017;49:145–154. doi: 10.4103/0253-7613.208143. [DOI] [PMC free article] [PubMed] [Google Scholar]

5.Bedse G., di Domenico F., Serviddio G., Cassano T. Aberrant insulin signaling in Alzheimer’s disease: Current knowledge. Front. Neurosci. 2015;9:204. doi: 10.3389/fnins.2015.00204. [DOI] [PMC free article] [PubMed] [Google Scholar]

6.Duarte J.M.N. Metabolic Alterations Associated to Brain Dysfunction in Diabetes. Aging Dis. 2015;6:304–321. doi: 10.14336/AD.2014.1104. [DOI] [PMC free article] [PubMed] [Google Scholar]

7.Nguyen T.T., Ta Q.T.H., Nguyen T.T.D., Le T.T., Vo V.G. Role of Insulin Resistance in the Alzheimer’s Disease Progression. Neurochem. Res. 2020 doi: 10.1007/s11064-020-03031-0. [DOI] [PubMed] [Google Scholar]

8.Caberlotto L., Nguyen T.P., Lauria M., Priami C., Rimondini R., Maioli S., Cedazo-Minguez A., Sita G., Morroni F., Corsi M., et al. Cross-disease analysis of Alzheimer’s disease and type-2 Diabetes highlights the role of autophagy in the pathophysiology of two highly comorbid diseases. Sci. Rep. 2019;9:3965. doi: 10.1038/s41598-019-39828-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

9.Correia S.C., Santos R.X., Carvalho C., Cardoso S., Candeias E., Santos M.S., Oliveira C.R., Moreira P.I. Insulin signaling, glucose metabolism and mitochondria: Major players in Alzheimer’s disease and diabetes interrelation. Brain Res. 2012;1441:64–78. doi: 10.1016/j.brainres.2011.12.063. [DOI] [PubMed] [Google Scholar]

10.Baker L.D., Cross D.J., Minoshima S., Belongia D., Watson G.S., Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch. Neurol. 2011;68:51–57. doi: 10.1001/archneurol.2010.225. [DOI] [PMC free article] [PubMed] [Google Scholar]

11.Ferreira L.S.S., Fernandes C.S., Vieira M.N.N., de Felice F.G. Insulin Resistance in Alzheimer’s Disease. Front. Neurosci. 2018;12:830. doi: 10.3389/fnins.2018.00830. [DOI] [PMC free article] [PubMed] [Google Scholar]

12.Rorbach-Dolata A., Piwowar A. Neurometabolic Evidence Supporting the Hypothesis of Increased Incidence of Type 3 Diabetes Mellitus in the 21st Century. Biomed. Res. Int. 2019;2019:8. doi: 10.1155/2019/1435276. [DOI] [PMC free article] [PubMed] [Google Scholar]

13.Ormazabal V., Nair S., Elfeky O., Aguayo C., Salomon C., Zuñiga F.A. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc. Diabetol. 2018;17:122. doi: 10.1186/s12933-018-0762-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

14.Weinstein G., Davis-Plourde K.L., Conner S., Himali J.J., Beiser A.S., Lee A., Rawlings A.M., Sedaghat S., Ding J., Moshier E., et al. Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer’s disease: Pooled analysis from 5 cohorts. PLoS ONE. 2019;14:e0212293. doi: 10.1371/journal.pone.0212293. [DOI] [PMC free article] [PubMed] [Google Scholar]

15.Hubbard S.R. The insulin receptor: Both a prototypical and atypical receptor tyrosine kinase. Cold Spring Harb. Perspect. Biol. 2013;5:a008946. doi: 10.1101/cshperspect.a008946. [DOI] [PMC free article] [PubMed] [Google Scholar]

16.Hubbard S.R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. Embo J. 1997;16:5572–5581. doi: 10.1093/emboj/16.18.5572. [DOI] [PMC free article] [PubMed] [Google Scholar]

17.Bosco D., Fava A., Plastino M., Montalcini T., Pujia A. Possible implications of insulin resistance and glucose metabolism in Alzheimer’s disease pathogenesis. J. Cell. Mol. Med. 2011;15:1807–1821. doi: 10.1111/j.1582-4934.2011.01318.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

18.Chiu S.L., Chen C.M., Cline H.T. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron. 2008;58:708–719. doi: 10.1016/j.neuron.2008.04.014. [DOI] [PMC free article] [PubMed] [Google Scholar]

19.Lee C.C., Huang C.C., Hsu K.S. Insulin promotes dendritic spine and synapse formation by the PI3K/Akt/mTOR and Rac1 signaling pathways. Neuropharmacology. 2011;61:867–879. doi: 10.1016/j.neuropharm.2011.06.003. [DOI] [PubMed] [Google Scholar]

20.Lee S.-H., Zabolotny J.M., Huang H., Lee H., Kim Y.-B. Insulin in the nervous system and the mind: Functions in metabolism, memory, and mood. Mol. Metab. 2016;5:589–601. doi: 10.1016/j.molmet.2016.06.011. [DOI] [PMC free article] [PubMed] [Google Scholar]

21.Peineau S., Taghibiglou C., Bradley C., Wong T.P., Liu L., Lu J., Lo E., Wu D., Saule E., Bouschet T., et al. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron. 2007;53:703–717. doi: 10.1016/j.neuron.2007.01.029. [DOI] [PubMed] [Google Scholar]

22.Kim S.J., Han Y. Insulin inhibits AMPA-induced neuronal damage via stimulation of protein kinase B (Akt) J. Neural Transm. (Vienna, Austria: 1996) 2005;112:179–191. doi: 10.1007/s00702-004-0163-6. [DOI] [PubMed] [Google Scholar]

23.Tomita T. Apoptosis in pancreatic β-islet cells in Type 2 diabetes. Bosn. J. Basic. Med. Sci. 2016;16:162–179. doi: 10.17305/bjbms.2016.919. [DOI] [PMC free article] [PubMed] [Google Scholar]

24.Havrankova J., Schmechel D., Roth J., Brownstein M. Identification of insulin in rat brain. Proc. Natl. Acad. Sci. USA. 1978;75:5737–5741. doi: 10.1073/pnas.75.11.5737. [DOI] [PMC free article] [PubMed] [Google Scholar]

25.Dorn A., Bernstein H.G., Rinne A., Ziegler M., Hahn H.J., Ansorge S. Insulin- and glucagonlike peptides in the brain. Anat. Rec. 1983;207:69–77. doi: 10.1002/ar.1092070108. [DOI] [PubMed] [Google Scholar]

26.Young W.S., 3rd Periventricular hypothalamic cells in the rat brain contain insulin mRNA. Neuropeptides. 1986;8:93–97. doi: 10.1016/0143-4179(86)90035-1. [DOI] [PubMed] [Google Scholar]

27.Gerozissis K. Brain insulin: Regulation, mechanisms of action and functions. Cell. Mol. Neurobiol. 2003;23:1–25. doi: 10.1023/A:1022598900246. [DOI] [PMC free article] [PubMed] [Google Scholar]

28.Clarke D.W., Mudd L., Boyd F.T., Jr., Fields M., Raizada M.K. Insulin is released from rat brain neuronal cells in culture. J. Neurochem. 1986;47:831–836. doi: 10.1111/j.1471-4159.1986.tb00686.x. [DOI] [PubMed] [Google Scholar]

29.Pomytkin I., Costa-Nunes J.P., Kasatkin V., Veniaminova E., Demchenko A., Lyundup A., Lesch K.-P., Ponomarev E.D., Strekalova T. Insulin receptor in the brain: Mechanisms of activation and the role in the CNS pathology and treatment. CNS Neurosci. Ther. 2018;24:763–774. doi: 10.1111/cns.12866. [DOI] [PMC free article] [PubMed] [Google Scholar]

Related Posts: